medigraphic.com
ISSN 0185-3325 (Print)
Órgano Oficial del Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz

2018, Number 6

<< Back Next >>

Salud Mental 2018; 41 (6)

Evaluation of the response of lisdexamfetamine in children and adolescents with ADHD: quasi-experimental study

Barragán PE, García BJC, Hidalgo GR

Language: English
References: 32
Page: 279-285
PDF size: 381.99 Kb.


ABSTRACT

Introduction. Attention deficit hyperactivity disorder (ADHD) is one of the most common neurodevelopmental disorders. Although lisdexamfetamine dimesylate (LDX) offers a treatment alternative, clinical evidence of LDX for ADHD has not been explored in Latin American pediatric population. Objective. To evaluate the LDX response in Mexican pediatric patients with ADHD. Method. We designed a quasi-experimental, uncontrolled before and after study to evaluate the LDX response in patients with severe ADHD. We established a diagnosis of ADHD according to DSM-5 criteria. We formed three groups: without previous treatment (group A), in treatment with stimulant drugs (group B) or in treatment with non-stimulant drugs (group C). Prior to the start of the study, letters of consent and informed consent were signed. We evaluated the effect of LDX based on the difference between ADHD-RS scores at the beginning and after six months. Results. We recruited a total of 144 patients (group A: 48 patients, group B: 57 patients, group C: 39 patients). All the groups showed a significant decrease in the mean score of ADHD-RS (Attention Deficit Hyperactivity Disorder Rating Scale) at six months (group A 37.57 vs. 22.34, p ‹.01), (group B 36.72 vs. 24.45; p ‹. 01), (group C 38.54 vs. 24.3, p ‹.01). Fewer than 30% of the subjects showed a significant adverse reaction, the most frequent ones being: sleep disturbance (primary insomnia) 24% and decreased appetite in 20%. Discussion and conclusion. Treatment with LDX is an effective, well-tolerated pharmacological option for Mexican pediatric patients with ADHD.


REFERENCES

  1. American Academy of Pediatrics. (2011). ADHD: Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. Pediatrics, 128(5), 1007-1022. doi: 10.1542/ peds.2011-2654

  2. Barragán-Pérez, E., de la Peña-Olvera, F., Ortiz-León, S., Ruiz-García, M., Hernández- Aguilar, J., Palacios-Cruz, L., & Suárez-Reynaga, A. (2007). Primer consenso latinoamericano de trastorno por déficit de atención e hiperactividad. Boletín médico del hospital infantil de México, 64(5), 326-343.

  3. Barragán, E., Breuer, D., & Döpfner, M. (2017). Efficacy and Safety of Omega- 3/6 Fatty Acids, Methylphenidate, and a Combined Treatment in Children with ADHD. Journal of Attention Disorders, 21(5), 433-441. doi: 10.1177/1087054713518239

  4. Biederman, J., Krishnan, S., Zhang, Y., McGough, J. J., & Findling, R. L. (2007). Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: A Phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study. Clinical Therapeutics, 29(3), 450-463. doi: 10.1016/S0149-2918(07)80083-X

  5. Boellner, S. W., Stark, J. G., Krishnan, S., & Zhang, Y. (2010). Pharmacokinetics of lisdexamfetamine dimesylate and its active metabolite, d-amphetamine, with increasing oral doses of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: A single-dose, randomized, open-label, crossover. Clinical Therapeutics, 32(2), 252-264. doi: 10.1016/j.clinthera. 2010.02.011

  6. Bolea-Alamañac, B., Nutt, D. J., Adamou, M., Asherson, P., Bazire, S., Coghill, D., … & Young, S. J. (2014). Evidence-based guidelines for the pharmacological management of attention deficit hyperactivity disorder: Update on recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology, 28(3), 179-203. doi: 10.1177/0269881113519509

  7. CADDRA. (2011). Canadian ADHD practice guidelines. Toronto: Canadian Attention Deficit Hyperactivity Disorder Resource Alliance.

  8. COFEPRIS. (2015). Comunicado de Prensa 07/15. Retrieved from: http://www.cofepris. gob.mx/Documents/NotasPrincipales/25012015.pdf

  9. Coghill, D., Banaschewski, T., Lecendreux, M., Soutullo, C., Johnson, M., Zuddas, A., … Squires, L. (2013). European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder. European Neuropsychopharmacology, 23(10), 1208-1218. doi: 10.1016/j.euroneuro.2012.11.012

  10. Coghill, D. R., Caballero, B., Sorooshian, S., & Civil, R. (2014). A Systematic Review of the Safety of Lisdexamfetamine Dimesylate. CNS Drugs, 28(6), 497- 511. doi: 10.1007/s40263-014-0166-2

  11. Diaz-Orueta, U., Fernandez-Fernandez, M. A., Morillo-Rojas, M. D., & Climent, G. (2016). Efficacy of lisdexamphetamine to improve the behavioural and cognitive symptoms of attention deficit hyperactivity disorder: treatment monitored by means of the AULA Nesplora virtual reality test. Revista de neurologia, 63(1), 19-27.

  12. Ermer, J. C., Pennick, M., & Frick, G. (2016). Lisdexamfetamine Dimesylate: Prodrug Delivery, Amphetamine Exposure and Duration of Efficacy. Clinical Drug Investigation, 36(5), 341-356. doi: 10.1007/s40261-015-0354-y

  13. Faraone, S. V. & Buitelaar, J. (2010). Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis. European Child & Adolescent Psychiatry, 19(4), 353-364. doi: 10.1007/s00787-009-0054-3

  14. Faraone, S. V, Sergeant, J., Gillberg, C., & Biederman, J. (2003). The worldwide prevalence of ADHD: is it an American condition? World psychiatry, 2(2), 104-113.

  15. Findling, R. L., Childress, A. C., Cutler, A. J., Gasior, M., Hamdani, M., Ferreira- Cornwell, M. C., & Squires, L. (2011). Efficacy and Safety of Lisdexamfetamine Dimesylate in Adolescents With Attention-Deficit/Hyperactivity Disorder. Journal of the American Academy of Child & Adolescent Psychiatry, 50(4), 395-405. doi: 10.1016/j.jaac.2011.01.007

  16. Findling, R. L., Cutler, A. J., Saylor, K., Gasior, M., Hamdani, M., Ferreira-Cornwell, M. C., & Childress, A. C. (2013). A Long-Term Open-Label Safety and Effectiveness Trial of Lisdexamfetamine Dimesylate in Adolescents With Attention- Deficit/Hyperactivity Disorder. Journal of Child and Adolescent Psychopharmacology, 23(1), 11-21. doi: 10.1089/cap.2011.0088

  17. Gonzalez-Covarrubias, V., Martínez-Magaña, J. J., Coronado-Sosa, R., Villegas-Torres, B., Genis-Mendoza, A. D., Canales-Herrerias, P., … & Soberón, X. (2016). Exploring Variation in Known Pharmacogenetic Variants and its Association with Drug Response in Different Mexican Populations. Pharmaceutical Research, 33(11), 2644-2652. doi: 10.1007/s11095-016-1990-5

  18. Goodman, D., Faraone, S. V, Adler, L. A., Dirks, B., Hamdani, M., & Weisler, R. (2010). Interpreting ADHD rating scale scores: linking ADHD rating scale scores and CGI levels in two randomized controlled trials of lisdexamfetamine dimesylate in ADHD. Primary Psychiatry, 17(3), 44.

  19. Hodgkins, P., Shaw, M., Caci, H., Young, S., Kahle, J., Woods, A. G., & Arnold, L. E. (2012). A systematic review and analysis of long-term outcomes in attention deficit hyperactivity disorder: Effects of treatment and non-treatment. BMC Medicine, 10(1), 99. doi: 10.1186/1741-7015-10-99

  20. Li, Y., Gao, J., He, S., Zhang, Y., & Wang, Q. (2017). An Evaluation on the Efficacy and Safety of Treatments for Attention Deficit Hyperactivity Disorder in Children and Adolescents: a Comparison of Multiple Treatments. Molecular Neurobiology, 54(9), 6655-6669. doi: 10.1007/s12035-016-0179-6

  21. Lopez, C. A. (2014). Manual diagnóstico y estadístico de los trastornos mentales: DSM-5. Editorial Médica Panamericana.

  22. National Institute for Health and Care Excellence. (2018). Attention deficit hyperactivity disorder: diagnosis and management. Guidance and guidelines NICE. Retrieved from https://www.nice.org.uk/guidance/NG87

  23. de la Peña, F., Barragán Pérez, E., Rohde, L. A., Durán, L. R. P., Ramírez, P. Z., Flores, R. E. U., … Larraguibel, M. (2009). Algoritmo de tratamiento multimodal para escolares latinoamericanos con trastorno por déficit de atención con hiperactividad (TDAH). Salud Mental, 32(S1), 17-29.

  24. Pérez, E. B. (2010). Las enfermedades neuropsiquiátricas en Latinoamérica y sus retos. Consejo Editorial 2009-2010, 78(4), 173.

  25. Polanczyk, G., de Lima, M. S., Horta, B. L., Biederman, J., & Rohde, L. A. (2007). The Worldwide Prevalence of ADHD: A Systematic Review and Metaregression Analysis. American Journal of Psychiatry, 164(6), 942-948. doi: 10.1176/ ajp.2007.164.6.942

  26. Polanczyk, G. V, Willcutt, E. G., Salum, G. A., Kieling, C., & Rohde, L. A. (2014). ADHD prevalence estimates across three decades: an updated systematic review and meta-regression analysis. International Journal of Epidemiology, 43(2), 434-442. doi: 10.1093/ije/dyt261

  27. Punja, S., Schmid, C. H., Hartling, L., Urichuk, L., Nikles, C. J., & Vohra, S. (2016). To meta-analyze or not to meta-analyze? A combined meta-analysis of N-of-1 trial data with RCT data on amphetamines and methylphenidate for pediatric ADHD. Journal of Clinical Epidemiology, 76, 76-81. doi: 10.1016/j.jclinepi. 2016.03.021

  28. Punja, S., Shamseer, L., Hartling, L., Urichuk, L., Vandermeer, B., Nikles, J., & Vohra, S. (2016). Amphetamines for attention deficit hyperactivity disorder (ADHD) in children and adolescents. Cochrane Database of Systematic Reviews. doi: 10.1002/14651858.CD009996.pub2

  29. Riera, M., Castells, X., Tobias, A., Cunill, R., Blanco, L., & Capellà, D. (2017). Discontinuation of pharmacological treatment of children and adolescents with attention deficit hyperactivity disorder: meta-analysis of 63 studies enrolling 11,788 patients. Psychopharmacology, 234(17), 2657-2671. doi: 10.1007/ s00213-017-4662-1

  30. Sosa-Macías, M., Teran, E., Waters, W., Fors, M. M., Altamirano, C., Jung-Cook, H., … & Hernández, F. (2016). Pharmacogenetics and ethnicity: relevance for clinical implementation, clinical trials, pharmacovigilance and drug regulation in Latin America. Pharmacogenomics, 17(16), 1741-1747. doi: 10.2217/pgs- 2016-0153

  31. Stuhec, M., Munda, B., Svab, V., & Locatelli, I. (2015). Comparative efficacy and acceptability of atomoxetine, lisdexamfetamine, bupropion and methylphenidate in treatment of attention deficit hyperactivity disorder in children and adolescents: A meta-analysis with focus on bupropion. Journal of Affective Disorders, 178, 149-159. doi: 10.1016/j.jad.2015.03.006

  32. Wang, L. J., Yang, K. C., Lee, S. Y., Yang, C. J., Huang, T. S., Lee, T. L., … Shyu, Y. C. (2016). Initiation and Persistence of Pharmacotherapy for Youths with Attention Deficit Hyperactivity Disorder in Taiwan. PLoS ONE, 11(8), e0161061. doi: 10.1371/journal.pone.0161061




2020     |     www.medigraphic.com